Are there candidates for high-dose chemotherapy in ovarian carcinoma?

Table 3 Prognostic parameters (PFS), Cox regression analysis

A. Whole population
	Univariate analysis				Multivariate analysis
	N	HR	95CI	p -value	N	HR	95CI	p -value
Age (>50y vs ≤50y)	163	1.12	0.76-1.66	0.57
OMS (0-1 vs 2-3)	117	1.53	0.88-2.67	0.14
FIGO (IIIc vs IV)	163	0.7	0.45-1.08	0.1
Histology (serous vs others)	163	0.95	0.66-1.39	0.8
Grade (1-2 vs 3)	98	1.2	0.93-1.55	0.16
Serous grade 3 (vs others)	98	1.42	0.80-2.52	0.23
Surgery (complete vs non complete)	160	0.38	0.26-0.54	2.23 E-07	147	0.57	0.37-0.87	0.01
Complete clinical remission (Yes vs No)	161	0.33	0.23-0.49	2.14 E-08	147	0.55	0.33-0.92	0.02
CA-125 (normal vs >normal)	149	0.45	0.29-0.71	6.9 E-04	147	0.77	0.45-1.32	0.34
Time from end of initial CT to HDC			NA
Treatment (CCA vs HDC)	163	1.39	0.95-2.03	0.09
B. According to chemotheraphy regimen, univariate analysis
	Conventional CT				High dose CT
	N	HR	95CI	p -value	N	HR	95CI	p -value
Age (>50y vs ≤50y)	103	0.83	0.52-1.33	0.44	60	2.03	0.96-4.29	0.06
OMS (0-1 vs 2-3)	78	1.56	0.84-2.89	0.16	39	0.96	0.22-4.17	0.95
FIGO (IIIc vs IV)	103	0.93	0.52-1.70	0.82	60	0.4	0.20-0.78	0.007
Histology (serous vs others)	103	1.24	0.78-1.97	0.37	60	0.83	0.44-1.58	0.56
Grade (1-2 vs 3)	62	1.17	0.85-1.61	0.35	36	1.08	0.67-1.72	0.76
Serous grade 3 (vs others)	62	0.81	0.57-1.15	0.24	36	0.98	0.51-1.87	0.94
Surgery (complete vs non complete)	100	0.29	0.18-0.46	2.2 E-07	60	0.65	0.34-1.22	0.18
Complete clinical remission (Yes vs No)	101	0.32	0.20-0.51	1.78 E-06	60	0.44	0.20-0.97	0.04
CA-125 (normal vs >normal)	91	0.32	0.18-0.56	6.41 E-05	58	1.21	0.53	2.74
Time from end of initial CT to HDC			NA		60	0.97	0.86-1.09	0.59
Treatment (CCA vs HDC)			NA				NA

PFS, progression-free survival; N, number of cases with data available; 95CI, 95% confidence interval; HR, hazard ratio; OMS, performance status; HDC, high-dose chemotherapy; CCA, conventional chemotherapy alone.